Novo Nordisk has announced 2025 total revenue of DKK 309.1 billion (approximately USD 46.8 billion), representing 10% growth at constant exchange rates. The diabetes and obesity care segments, which account for 94% of total sales, generated combined revenue of about USD 43.9 billion. Sales of the company's GLP-1-based medicines, led by the semaglutide products Ozempic, Rybelsus and Wegovy, reached DKK 234.5 billion (USD 35.6 billion), an increase of 14%. The three semaglutide products collectively generated USD 34.6 billion in sales.

While Novo Nordisk's global market share in GLP-1 diabetes drugs declined to 45.8% amid competitive pressure, it maintained a dominant 83.1% share of the Chinese GLP-1 market for diabetes. The company's revenue in China grew 5% to DKK 18.7 billion (USD 2.8 billion). For 2026, Novo Nordisk forecasts a sales decline of 5% to 13% at constant exchange rates, reflecting expected pricing pressures and market dynamics.

PharmCube's NextBiopharm® database shows that, in addition to metabolism, Novo's portfolio covers areas such as oncology, neurology, cardiovascular diseases, and immunology. Click here to request a free trial for NextBiopharm®.